Optiver Holding
TBPH icon

Optiver Holding’s Theravance Biopharma TBPH Stock Holding History

Optiver Holding’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.29K Buy
264
+38
+17% +$672 ﹤0.01% 1487
2025
Q4 		$4.23K Buy
226
+32
+16% +$531 ﹤0.01% 1483
2025
Q3 		$2.83K Buy
+194
New +$2.45K ﹤0.01% 2222

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Optiver Holding's TBPH Position: Q1 2026 in Review

Optiver Holding increased its Theravance Biopharma (TBPH) stake by 17% in Q1 2026, buying an estimated $672 and bringing the position to 264 shares worth $4.29K. The position accounts for ﹤0.01% of the portfolio, ranked #1487.

Optiver Holding first reported a position in TBPH in Q3 2025 and has held it in 3 quarters since. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Optiver Holding held 264 shares of Theravance Biopharma worth $4.29K as of Q1 2026.
  • Optiver Holding bought 38 Theravance Biopharma shares in Q1 2026, an estimated $672.
  • Theravance Biopharma made up ﹤0.01% of Optiver Holding's portfolio in Q1 2026, its #1487 holding.
  • Optiver Holding first reported a position in Theravance Biopharma in Q3 2025 and has held it in 3 quarters since.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.